BioSpace News Archive

Business

Merus Announces Third Quarter 2017 Financial Results and Clinical Highlights

Merus ended the third quarter of 2017 with cash and cash equivalents of €202.4 million compared to €56.9 million at December 31, 2016.

November 30, 2017

·

10 min read

ALK Secures Pricing and Reimbursement for ACARIZAX in France

A marketing authorisation for France was first granted in January 2016 and since then, ALK has been in dialogue with the authorities to secure market access for the product.

November 30, 2017

·

2 min read

Pharm Country

Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine

On the eve of World AIDS Day Johnson & Johnson announced that its Janssen Pharmaceutical Companies together with a consortium of global partners have initiated the first efficacy study for an investigational mosaic HIV-1 preventive vaccine.

November 30, 2017

·

8 min read

Policy

EMA Accepts MAAs for Mylan and Biocon’s Proposed Biosimilars Trastuzumab and Pegfilgrastim

EMA acceptance of the submissions follows an earlier withdrawal of both applications in response to an audit conducted by the European inspecting authority of Biocon’s drug product facility.

November 30, 2017

·

7 min read

Tikcro Technologies Announces 2017 Annual General Meeting

Tikcro Technologies today announced that its Annual General Meeting of Shareholders will be held on January 4, 2018 at 9:30 a.m. Israel time, at the office of the Company at 7 Sapir Street, Ness Ziona, Israel.

November 30, 2017

·

1 min read

Drug Development

Novartis’ Cosentyx is First Biologic to Show Long-Term Efficacy in Nail and Palmoplantar Psoriasis, Which Can Impact Up to 90% of Psoriasis Patients

These new data from a clinical study were presented at the 8th International Congress of Psoriasis from Gene to Clinic in London, UK.

November 30, 2017

·

15 min read

Drug Development

TRACON Doses First Patient in Phase Ib Study of TRC105 With Opdivo in Patients With Lung Cancer

The Phase 1b clinical trial is an open-label, dose-escalation and expansion cohort study of TRC105 and Opdivo in patients with non-small cell lung cancer that have received prior chemotherapy.

November 30, 2017

·

3 min read

FDA

Amphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USP

Amphastar’s newly approved products were determined by the FDA to be therapeutically equivalent to Depo-Provera Contraceptive Injection sold in the United States by Pfizer.

November 30, 2017

·

3 min read

Biotech Beach

UC Irvine Release: Effort to Create Mouse That More Closely Mirrors Human Alzheimer’s Wins Federal Grant

A proposal to humanize several mouse genes for research into Alzheimer’s disease has spurred the National Institute on Aging to award $11.35M to the University of California, Irvine.

November 30, 2017

·

2 min read

Deals

Corazon and NanoSphere Announce Completion of $5.9M Financing and Merger

Based upon the CSE’s conditional listing approval, the Company will make its final submission for CSE listing in short order, and concurrently with its listing on the CSE will change its name to “NanoSphere Health Sciences Inc.” and effect a de-listing from the TSX Venture Exchange.

November 30, 2017

·

6 min read